Be the first to know

Never miss an update from Gilead Sciences. Did you know that during reporting season, the announcements from NASDAQ:GILD often move the market?

Gilead Sciences (NASDAQ:GILD) Company Logo

By joining StockLight, you agree to our Terms & Conditions and Privacy Policy
Create Alert Follow GILD

Gilead Sciences (GILD)

US NASDAQ:GILD (97.2B)

76.79
-0.74 (-0.97%)
4:22pm EDT
LOADING
Loading price chart..

Summary

Current Price: $76.79
52w High/Low: $60.89 - 85.97
Market Cap: 97.2B
Price/Earnings: 19.57
Dividend Yield: 3.30%
Volume/Average: 11M - 19.1M
Gilead Sciences (NASDAQ:GILD) Company Logo

Listed in 1992

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need... More
Gilead Sciences (NASDAQ:GILD) Company Logo

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.

Annual Reports

Gilead Sciences (GILD) 10-K Annual Report Feb 25th 2020
2020
(165kb)
Gilead Sciences (GILD) 10-K Annual Report Apr 18th 2019
2019
(155kb)
Gilead Sciences (GILD) 10-K Annual Report Feb 26th 2019
2019
(155kb)
Gilead Sciences (GILD) 10-K Annual Report Feb 27th 2018
2018
(159kb)
Gilead Sciences (GILD) 10-K Annual Report Feb 27th 2017
2017
(1.4mb)
Gilead Sciences (GILD) 10-K Annual Report Feb 24th 2016
2016
(1.3mb)

Dividend History

Quantitative Ratios

Stock Ratios Locked
You viewed 3 companies today
Ratios will be unlocked
again tomorrow or;

Unlock these ratios,
configure alerts
and much more...

Download StockLight

All Ratios, Alerts and other features are available in our iOS and Android apps:
Download on iOS Download on Android

We are working on updating this web app to fully enable Quantitative Ratios. All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app.
Dividend Yield
1.9%
 
3.3%
 
 
Industry Avg
GILD

ATTRACTIVE: Gilead Sciences's dividend yield of 3.3% exceeds the industry average for biotechnology stocks listed on the NASDAQ. more
Implied Growth
49.8%
 
4.9%
 
 
Industry Avg
GILD

ATTRACTIVE: Gilead Sciences exhibits an implied growth ratio which is less than the industry average for biotechnology stocks listed on the NASDAQ. GILD calculation: 10% - ($3.90 / $76.79) = 4.9% more
Price / Book
4.8
 
4.4
 
 
Industry Avg
GILD

AVERAGE: Gilead Sciences exhibits a price/book ratio which is within a 15% range of the industry average for biotechnology stocks listed on the NASDAQ. more
Price / Earnings
24.7
 
19.9
 
 
Industry Avg
GILD

ATTRACTIVE: Gilead Sciences's price/earnings ratio of 19.9 is less than the industry average for biotechnology stocks listed on the NASDAQ. more
Price / Sales
23.3
 
4.3
 
 
Industry Avg
GILD

ATTRACTIVE: Gilead Sciences exhibits a price/sales ratio which is less than the industry average for biotechnology stocks listed on the NASDAQ. more

Company News

Is Remdesivir a Disappointment?
June 4th, 2020 - Motley Fool

Investors seem to think so based on new data for Gilead Sciences' potential COVID-19 treatment.

Better Buy: Bristol Myers Squibb vs. Gilead Sciences
June 4th, 2020 - Motley Fool

Which of these household names is the better buy?

Biotech Stocks: Buy This, Not That
June 4th, 2020 - Motley Fool

Here's how one biotech company can make investors rich, and why another should be avoided.

Better Coronavirus Stock: Gilead Sciences or Novavax?
June 2nd, 2020 - Motley Fool

Between a big biotech with the leading COVID-19 therapy and a small biotech with a promising COVID-19 vaccine candidate, which stock wins?

Why Carnival, Royal Caribbean, and Norwegian Cruise Line Stocks Rose Today
June 1st, 2020 - Motley Fool

Cruise ship investors cheered hopeful coronavirus news.

Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win
June 1st, 2020 - Motley Fool

The company is an aggressive newcomer to the infectious-disease market and its COVID-19 programs are very promising.

Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today
May 29th, 2020 - Motley Fool

The development-stage biopharma is bouncing back from a recent stock dip.

Don't Waste Your Money on Penny Stocks; These 3 Are Better Buys
May 28th, 2020 - Motley Fool

Unlike most penny stocks, these three companies are leaders in their respective industries and could provide market-beating returns for a while.